Although the removal of nasal polyps with a massive amount of eosinophilic mucin by ESS can temporarily normalize the condition in a local area, patients with severe ECRS possess a high risk of recurrence of eosinophilic airway inflammation with mucin formulation [8]. The gene discussed is MUC5AC; the disease is Nasal polyposis.